Topotecan-d6

• UNSPSC Description:

  Topotecan-d6 is the deuterium labeled Topotecan. Topotecan (SKF 104864A; NSC 609669) is a Topoisomerase I inhibitor. The IC50 values of Topotecan at 24 h are 2.73±0.25 μM of U251 cells, 2.95±0.23 μM of U87 cells, 5.46±0.41 μM of GSCs-U251 and 5.95 μM of GSCs-U87[1][2].

• Target Antigen:

  Autophagy; Isotope-Labeled Compounds; Topoisomerase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Cell Cycle/DNA Damage;Others

• Field of Research:

  Cancer

• Smiles:

  CC[C@@]1(C2=C(COC1=O)C(N3C(C(C(C3)=CC4=C5CN(C([2H])([2H])[2H])C([2H])([2H])[2H])=NC4=CC=C5O)=C2)=O)O

• Molecular Weight:

  427.48

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Zhang FL, et al. PLoS One. 2013 Nov 26;8(11):e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[3]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17(17):5656-67.

• Shipping Conditions:

  Blue Ice

• CAS Number:

  1044904-10-0